MX2017004440A - Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. - Google Patents
Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.Info
- Publication number
- MX2017004440A MX2017004440A MX2017004440A MX2017004440A MX2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- inhalable
- pulmonary hypertension
- rapamycin formulation
- rapamycin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con métodos y composiciones para el tratamiento y profilaxis de hipertensión arterial pulmonar (AHP) en un sujeto humano que necesite tal tratamiento, los métodos que comprenden la administración pulmonar al sujeto, de preferencia por inhalación de una composición que comprende rapamicina o un profármaco o derivado del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462060988P | 2014-10-07 | 2014-10-07 | |
US201562144145P | 2015-04-07 | 2015-04-07 | |
PCT/US2015/054550 WO2016057712A1 (en) | 2014-10-07 | 2015-10-07 | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004440A true MX2017004440A (es) | 2017-11-01 |
Family
ID=54360545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004440A MX2017004440A (es) | 2014-10-07 | 2015-10-07 | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20170304276A1 (es) |
EP (1) | EP3209330B1 (es) |
JP (1) | JP6679584B2 (es) |
KR (1) | KR20170095807A (es) |
CN (1) | CN107249576A (es) |
AU (1) | AU2015330905B2 (es) |
BR (1) | BR112017006842A2 (es) |
CA (1) | CA2963085C (es) |
IL (1) | IL251385B (es) |
MX (1) | MX2017004440A (es) |
RU (1) | RU2732908C2 (es) |
WO (1) | WO2016057712A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3054948B1 (en) | 2013-10-08 | 2020-08-12 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
FI3125875T3 (fi) | 2014-04-04 | 2023-08-24 | Ai Therapeutics Inc | Inhaloitava rapamysiiniformulaatio ikäsidonnaisten tilojen hoitoon |
MX2017004440A (es) | 2014-10-07 | 2017-11-01 | Lam Therapeutics Inc | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. |
EP3452170A4 (en) | 2016-05-05 | 2020-04-01 | Liquidia Technologies, Inc. | DRY POWDER OF TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION |
PT3505157T (pt) * | 2017-12-29 | 2022-02-18 | Celon Pharma Sa | Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento |
EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
CN112423737A (zh) * | 2018-05-22 | 2021-02-26 | 阿布拉科斯生物科学有限公司 | 用于治疗肺高压的方法和组合物 |
AU2020241730A1 (en) * | 2019-03-19 | 2021-10-28 | Abraxis Bioscience, Llc | Subcutaneous administration of nanoparticles comprising an mTOR inhibitor and albumin for treatment of diseases |
CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2517482A (en) | 1949-04-09 | 1950-08-01 | Sharp & Dohme Inc | Inhaler |
GB1242211A (en) | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
DE3345722A1 (de) | 1983-12-17 | 1985-06-27 | Boehringer Ingelheim KG, 6507 Ingelheim | Inhalator |
GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
DE4140689B4 (de) | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
AU688782B2 (en) | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
HUT77373A (hu) | 1994-09-29 | 1998-03-30 | Andaris Limited | Porlasztva szárított mikrorészecskék gyógyszerészeti hordozóként |
US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
DE19523516C1 (de) * | 1995-06-30 | 1996-10-31 | Asta Medica Ag | Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
BR9713661A (pt) | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulação e método para o tratamento de neoplasmas por inalação |
US6451784B1 (en) | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US20040039047A1 (en) | 1998-08-11 | 2004-02-26 | Mark Zamoyski | Compositions and methods for treating lung cancers |
DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
CA2457148A1 (en) | 2001-08-20 | 2003-02-27 | Transave, Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
EP1424889A4 (en) | 2001-08-20 | 2008-04-02 | Transave Inc | PROCESS FOR TREATING LUNG CANCERS |
WO2003099362A1 (en) | 2002-05-20 | 2003-12-04 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
US20050070567A1 (en) | 2002-08-12 | 2005-03-31 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
AU2003269989B8 (en) * | 2002-08-21 | 2009-11-12 | Norton Healthcare Ltd. | Inhalation composition |
TR200502189T1 (tr) | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. |
UA83484C2 (uk) | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
AR043504A1 (es) | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
AR050374A1 (es) | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
US20060094744A1 (en) | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
FR2882366B1 (fr) | 2005-02-18 | 2008-04-18 | Coletica Sa | Polymere reticule de carbohydrate, notamment a base de polysaccharides et/ou de polyols |
KR20070107087A (ko) | 2005-03-02 | 2007-11-06 | 와이어쓰 | 라파마이신의 정제 |
US20080275076A1 (en) * | 2005-03-08 | 2008-11-06 | Per Holm | Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof |
EP1868576A2 (en) | 2005-03-17 | 2007-12-26 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
CN1883474A (zh) | 2005-06-22 | 2006-12-27 | 华北制药集团新药研究开发有限责任公司 | 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物 |
US7446096B2 (en) | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
TW200731967A (en) | 2005-12-20 | 2007-09-01 | Wyeth Corp | Control of CCI-779 dosage form stability through control of drug substance impurities |
CA2637255C (en) | 2006-02-02 | 2018-06-12 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders |
GB0602123D0 (en) | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2008022256A2 (en) | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
CA2669714A1 (en) | 2006-11-10 | 2008-05-15 | Biocon Limited | A pure form of rapamycin and a process for recovery and purification thereof |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
EP2086602A2 (en) | 2006-11-20 | 2009-08-12 | Lutonix, Inc. | Drug releasing coatings for medical devices |
EP1938800A1 (en) | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
EP1952807A1 (en) | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
EP2129379B1 (en) | 2007-02-20 | 2019-04-10 | Novartis AG | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
CA2686736A1 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
US20090208582A1 (en) | 2008-02-13 | 2009-08-20 | Board Of Regents, The University Of Texas System | Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary Delivery |
PT2365802T (pt) * | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
CN102292072A (zh) | 2009-01-26 | 2011-12-21 | 特瓦制药工业有限公司 | 用微粒包衣载体的方法 |
US20100196483A1 (en) | 2009-02-04 | 2010-08-05 | Activaero Gmbh Research & Development | Method for treatmentof severe and uncontrollable asthma |
GB0905818D0 (en) | 2009-04-06 | 2009-05-20 | Airbus Uk Ltd | Coupling assembly |
CN104997774A (zh) | 2009-04-10 | 2015-10-28 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
GB0908129D0 (en) | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
US9248110B2 (en) * | 2010-03-18 | 2016-02-02 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis |
PT105058B (pt) * | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
WO2011163600A2 (en) | 2010-06-25 | 2011-12-29 | Apt Pharmaceuticals, Inc. | Tacrolimus compositions for aerosol administration |
US20140037548A1 (en) * | 2010-06-28 | 2014-02-06 | The Board Of Trustees Of The Leland Standford Junior University | Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors |
WO2012047674A2 (en) | 2010-09-27 | 2012-04-12 | Microdose Therapeutx, Inc. | Methods and compositions for disease treatment using inhalation |
CN102670518B (zh) * | 2011-03-14 | 2014-08-20 | 齐鲁制药有限公司 | 一种难溶性药物球形颗粒的制备方法 |
US20140067548A1 (en) | 2012-08-31 | 2014-03-06 | Sap Ag | Saving on device functionality for business calendar |
EP3721784B1 (en) | 2013-03-28 | 2023-12-20 | EndoChoice, Inc. | Compact multi-viewing element endoscope system |
EP3054948B1 (en) * | 2013-10-08 | 2020-08-12 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
CN106573067A (zh) * | 2014-02-11 | 2017-04-19 | 拉姆医疗公司 | 用于淋巴管平滑肌瘤病治疗的雷帕霉素 |
US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
FI3125875T3 (fi) | 2014-04-04 | 2023-08-24 | Ai Therapeutics Inc | Inhaloitava rapamysiiniformulaatio ikäsidonnaisten tilojen hoitoon |
DE102014005466A1 (de) | 2014-04-12 | 2015-10-15 | Klaus Düring | Verfahren zur Gewinnung von Napin und Cruciferin oder einem Gemisch davon aus Raps |
MX2017004440A (es) | 2014-10-07 | 2017-11-01 | Lam Therapeutics Inc | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. |
MA40910A (fr) * | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
CN108039392A (zh) | 2017-11-06 | 2018-05-15 | 北京汉能薄膜发电技术有限公司 | 铜铟镓硒化合物、油墨及其薄膜吸收层制备方法 |
-
2015
- 2015-10-07 MX MX2017004440A patent/MX2017004440A/es unknown
- 2015-10-07 RU RU2017115990A patent/RU2732908C2/ru active
- 2015-10-07 CN CN201580066403.9A patent/CN107249576A/zh active Pending
- 2015-10-07 US US15/516,219 patent/US20170304276A1/en not_active Abandoned
- 2015-10-07 KR KR1020177010965A patent/KR20170095807A/ko not_active Application Discontinuation
- 2015-10-07 WO PCT/US2015/054550 patent/WO2016057712A1/en active Application Filing
- 2015-10-07 JP JP2017518487A patent/JP6679584B2/ja active Active
- 2015-10-07 AU AU2015330905A patent/AU2015330905B2/en active Active
- 2015-10-07 BR BR112017006842A patent/BR112017006842A2/pt not_active Application Discontinuation
- 2015-10-07 EP EP15787076.7A patent/EP3209330B1/en active Active
- 2015-10-07 CA CA2963085A patent/CA2963085C/en active Active
-
2017
- 2017-03-26 IL IL251385A patent/IL251385B/en unknown
-
2019
- 2019-12-27 US US16/728,615 patent/US11491143B2/en active Active
-
2022
- 2022-10-14 US US17/965,859 patent/US20230255944A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015330905B2 (en) | 2021-02-25 |
US20230255944A1 (en) | 2023-08-17 |
BR112017006842A2 (pt) | 2017-12-12 |
CA2963085C (en) | 2023-02-21 |
KR20170095807A (ko) | 2017-08-23 |
US11491143B2 (en) | 2022-11-08 |
US20200306230A1 (en) | 2020-10-01 |
IL251385A0 (en) | 2017-05-29 |
RU2732908C2 (ru) | 2020-09-24 |
CN107249576A (zh) | 2017-10-13 |
US20170304276A1 (en) | 2017-10-26 |
WO2016057712A1 (en) | 2016-04-14 |
EP3209330B1 (en) | 2022-02-23 |
RU2017115990A (ru) | 2018-11-13 |
JP6679584B2 (ja) | 2020-04-15 |
RU2017115990A3 (es) | 2019-05-08 |
EP3209330A1 (en) | 2017-08-30 |
JP2017534604A (ja) | 2017-11-24 |
NZ731059A (en) | 2023-12-22 |
AU2015330905A1 (en) | 2017-05-18 |
CA2963085A1 (en) | 2016-04-14 |
IL251385B (en) | 2022-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004103A (es) | Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad. | |
MX2017004440A (es) | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. | |
MX2016010373A (es) | Rapamicina para el tratamiento de linfangioleiomiomatosis. | |
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
PL3307289T3 (pl) | Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt) | |
MX2016004530A (es) | Rapamicina para el tratamiento de linfangioleiomiomatosis. | |
MX2016013486A (es) | Activadores de canales ionicos y metodos de uso. | |
EA201692422A1 (ru) | Состав, содержащий пролекарство гемцитабина | |
PH12018500544A1 (en) | Inhalable nicotine formulations, and methods of making and using thereof | |
MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
MX2017002803A (es) | Coronavirus bovino atenuado y vacunas relacionadas. | |
IN2013MU03583A (es) | ||
EA036036B1 (ru) | Композиции, содержащие циклоспорин | |
PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
MX2017004760A (es) | Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. | |
MX2017014301A (es) | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. | |
MX2017003016A (es) | Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas. | |
IL257689A (en) | Pharmacological preparations and methods for the treatment of diseases associated with hypoxia | |
TW201613563A (en) | Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof | |
IN2014DE00822A (es) |